| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/17/2004 | CA2507011A1 Phosphoantigens for regulating an immune response |
| 06/17/2004 | CA2506965A1 Use of levocetirizine for the treatment of persistent allergic rhinitis |
| 06/17/2004 | CA2506727A1 Treatment of huntington's disease with epa |
| 06/17/2004 | CA2506546A1 Kinase modulators |
| 06/17/2004 | CA2505857A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| 06/17/2004 | CA2505783A1 The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence |
| 06/17/2004 | CA2505298A1 Methods and compositions for applying pharmacologic agents to the ear |
| 06/17/2004 | CA2505150A1 Aza-peptides |
| 06/17/2004 | CA2505106A1 Concentrated liquid valdecoxib composition |
| 06/17/2004 | CA2504740A1 Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents |
| 06/17/2004 | CA2498089A1 Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| 06/17/2004 | CA2488114A1 Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof |
| 06/17/2004 | CA2453387A1 Compositions and methods related to nitrotyrosine-containing compounds as antigenic agents |
| 06/17/2004 | CA2414500A1 Agonist-aversive combination medicines |
| 06/16/2004 | WO2004054978A1 Quinoline derivative as diagnostic probe for disease with tau protein accumulation |
| 06/16/2004 | EP1428826A2 Crystal forms of cytostatics |
| 06/16/2004 | EP1428825A1 Benzimidazole derivatives |
| 06/16/2004 | EP1428824A1 Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 06/16/2004 | EP1428822A2 1-phenylpiperazine derivative as modulators of dopamine neurotransmission |
| 06/16/2004 | EP1428821A1 Piperidin-4-yl amines with analgesic effect |
| 06/16/2004 | EP1428820A1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications |
| 06/16/2004 | EP1428538A1 Ectocornea extension promoters |
| 06/16/2004 | EP1428535A1 Controlled delivery of antidepressants |
| 06/16/2004 | EP1428534A1 Benzofurazan derivatives for enhancing glutamatergic synaptic responses |
| 06/16/2004 | EP1428533A2 Use of thiazolidine- or pyrrolidine-derivatives of aminoacids as antihyperglycemic agents |
| 06/16/2004 | EP1428532A1 Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| 06/16/2004 | EP1428531A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
| 06/16/2004 | EP1428529A1 Apolipo protein e secretion promoters |
| 06/16/2004 | EP1428528A1 Synergistic combinations of dietary fiber and NSAIDs for the treatment of cancer |
| 06/16/2004 | EP1428527A1 Novel formulations for transdermal delivery of pergolide |
| 06/16/2004 | EP1428526A1 Formulation for fast dissolution of lipophilic compounds |
| 06/16/2004 | EP1428525A1 Pharmaceutical preparations for the veterinary use containing acetylsalicylic acid in the form of buffered soluble powder |
| 06/16/2004 | EP1428524A1 Pulmonary delivery of aerosolized medicaments |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427849A2 Method of screening for drug hypersensitivity reaction |
| 06/16/2004 | EP1427831A1 Yeast membrane protein expression system and its application in drug screening |
| 06/16/2004 | EP1427825A2 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 06/16/2004 | EP1427810A2 Method and quantification assay for determining c-kit/scf/pakt status |
| 06/16/2004 | EP1427806A2 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 06/16/2004 | EP1427758A2 Compositions and methods of treating diabetes |
| 06/16/2004 | EP1427748A1 17alpha-hydroxy-14beta-steroids with hormonal effect |
| 06/16/2004 | EP1427739A1 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum |
| 06/16/2004 | EP1427734A1 GLYCINE-SUBSTITUTED THIENO 2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY |
| 06/16/2004 | EP1427733A1 Thieno 2,3-d]pyrimidines with combined lh and fsh agonistic activity |
| 06/16/2004 | EP1427732A1 Spirocyclic-6,7-dihydro-5h-pyrazolo 1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 06/16/2004 | EP1427730A1 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| 06/16/2004 | EP1427729A1 Carbazole derivatives and their use as npy5 receptor antagonists |
| 06/16/2004 | EP1427728A1 6,7-DIHYDRO-5H-PYRAZOLO 1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY cYTOKINES |
| 06/16/2004 | EP1427727A1 Compounds which inhibit the release of inflammatory cytokines |
| 06/16/2004 | EP1427724A1 Novel use of substituted aminomethyl chromans |
| 06/16/2004 | EP1427723A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 06/16/2004 | EP1427722A2 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression |
| 06/16/2004 | EP1427720A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427718A1 Benzothiepine ileal bile acid transport inhibotors |
| 06/16/2004 | EP1427717A1 Bioprecursors for percutaneous application |
| 06/16/2004 | EP1427713A1 Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 06/16/2004 | EP1427712A2 Dye-azide compounds for dual phototherapy |
| 06/16/2004 | EP1427711A1 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents |
| 06/16/2004 | EP1427709A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427708A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/16/2004 | EP1427707A1 Substituted indazole compounds for the treatment of inflammation |
| 06/16/2004 | EP1427706A1 Substituted pyrazolo compounds for the treatment of inflammation |
| 06/16/2004 | EP1427696A1 Ccr-3 receptor antagonists v |
| 06/16/2004 | EP1427482A2 Method and apparatus for acne treatment |
| 06/16/2004 | EP1427457A1 Medical devices containing rapamycin analogs |
| 06/16/2004 | EP1427450A2 Inhibition of rna function by delivery of inhibitors to animal cells |
| 06/16/2004 | EP1427447A1 Improved therapeutic protocols |
| 06/16/2004 | EP1427446A2 The use of effect pigments in ingested drugs |
| 06/16/2004 | EP1427436A2 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
| 06/16/2004 | EP1427435A1 Method for re-sensitizing vancomycin resistant bacteria using agents which selectively cleave a cell wall depsipeptide |
| 06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
| 06/16/2004 | EP1427429A1 Compositions and methods for treating subjects with hyperglycemia |
| 06/16/2004 | EP1427427A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 06/16/2004 | EP1427425A1 Method of treatment of obesity and paralyzed muscle and ergogenic aids |
| 06/16/2004 | EP1427424A2 Lpa receptor agonists and antagonists and methods of use |
| 06/16/2004 | EP1427423A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| 06/16/2004 | EP1427422A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
| 06/16/2004 | EP1427421A1 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents |
| 06/16/2004 | EP1427420A1 Use of 4-pyridylmethylphthalazines for cancer treatment |
| 06/16/2004 | EP1427418A2 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment |
| 06/16/2004 | EP1427417A1 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents |
| 06/16/2004 | EP1427416A2 3-glyoxlylamideindoles for treating cancer |
| 06/16/2004 | EP1427415A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| 06/16/2004 | EP1427414A1 Inhalation compositions comprising tricyclic 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines |
| 06/16/2004 | EP1427413A2 2-aroylimidazole compounds for treating cancer |
| 06/16/2004 | EP1427412A1 Methods of treating cytokine mediated diseases |
| 06/16/2004 | EP1427411A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo 3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 06/16/2004 | EP1427410A1 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration |
| 06/16/2004 | EP1427409A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
| 06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
| 06/16/2004 | EP1427406A2 Modulation of stat activity |
| 06/16/2004 | EP1427405A2 Inflammation-inhibiting compounds |
| 06/16/2004 | EP1427404A2 Treatment of glial tumors with glutamate antagonists |
| 06/16/2004 | EP1427403A2 Valproic acid and derivatives for the combination treatment of human cancers, tumor metastasis and minimal residual disease |
| 06/16/2004 | EP1427402A1 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| 06/16/2004 | EP1427401A2 Method for reducing hypertension and heart failure |
| 06/16/2004 | EP1427400A2 Triclosan dosage form |
| 06/16/2004 | EP1427399A2 Retinoid receptor pan-antagonists for stimulating chondrogenesis |
| 06/16/2004 | EP1427398A1 Device for the administration of an active agent to the human skin |
| 06/16/2004 | EP1427396A1 Dosage forms having prolonged active ingredient release |